DE60022327T2 - Lipoxinverbindungen und ihre anwendung - Google Patents

Lipoxinverbindungen und ihre anwendung Download PDF

Info

Publication number
DE60022327T2
DE60022327T2 DE60022327T DE60022327T DE60022327T2 DE 60022327 T2 DE60022327 T2 DE 60022327T2 DE 60022327 T DE60022327 T DE 60022327T DE 60022327 T DE60022327 T DE 60022327T DE 60022327 T2 DE60022327 T2 DE 60022327T2
Authority
DE
Germany
Prior art keywords
atla
lxa
lipoxin
pmn
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60022327T
Other languages
German (de)
English (en)
Other versions
DE60022327D1 (de
Inventor
N. Charles SERHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of DE60022327D1 publication Critical patent/DE60022327D1/de
Publication of DE60022327T2 publication Critical patent/DE60022327T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
DE60022327T 1999-03-18 2000-03-14 Lipoxinverbindungen und ihre anwendung Expired - Lifetime DE60022327T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12520999P 1999-03-18 1999-03-18
US125209P 1999-03-18
PCT/US2000/006583 WO2000055109A1 (en) 1999-03-18 2000-03-14 Lipoxin compounds and their use

Publications (2)

Publication Number Publication Date
DE60022327D1 DE60022327D1 (de) 2005-10-06
DE60022327T2 true DE60022327T2 (de) 2006-06-29

Family

ID=22418667

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022327T Expired - Lifetime DE60022327T2 (de) 1999-03-18 2000-03-14 Lipoxinverbindungen und ihre anwendung

Country Status (12)

Country Link
US (8) US6433202B1 (enExample)
EP (1) EP1163204B1 (enExample)
JP (1) JP2002539181A (enExample)
AT (1) ATE303355T1 (enExample)
AU (2) AU776271B2 (enExample)
CA (2) CA2365204C (enExample)
DE (1) DE60022327T2 (enExample)
DK (1) DK1163204T3 (enExample)
ES (1) ES2246230T3 (enExample)
HK (1) HK1043357B (enExample)
PT (1) PT1163204E (enExample)
WO (1) WO2000055109A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000054767A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response
ES2246230T3 (es) * 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
AU780114B2 (en) * 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US6409541B1 (en) * 2000-11-02 2002-06-25 Autonetworks Technologies, Ltd. Waterproof structure in cable insertion section, method of manufacturing the same, and die for waterproof molding
WO2002065303A1 (en) * 2001-02-13 2002-08-22 Fujitsu Limited Network terminal having power saving mode
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
JP2005508282A (ja) * 2001-03-02 2005-03-31 ザ・ブリガム・アンド・ウイメンズ・ホスピタル 新規な脈管形成抑制剤としてのリポキシン類似物
GB0119583D0 (en) * 2001-08-10 2001-10-03 Unilever Plc Cosmetic composition and method of treating skin
WO2003039533A1 (en) * 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US6831186B2 (en) 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
DE60318456T2 (de) 2002-06-17 2008-12-24 Resolvyx Pharmaceuticals, Bedford ANALOGA VON OMEGA-3-PUFAs ABGELEITETEN LIPIDMEDIATOREN UND ANWENDUNGSVERFAHREN
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
DK2216318T3 (en) * 2002-08-12 2018-12-10 Brigham & Womens Hospital Resolvins: Bio templates for therapeutic interventions
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
EP1755537A4 (en) * 2004-04-14 2009-12-09 Univ Boston METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING PERIODONTOPATHIA
WO2007041440A2 (en) * 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
US8636986B2 (en) * 2005-11-18 2014-01-28 The Forsyth Institute Treatment and prevention of bone loss using resolvins
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
JP5749651B2 (ja) 2008-11-04 2015-07-15 インデックス・ファーマシューティカルズ・アクチエボラーグ 多形核細胞の動員および／または遊走を減少させる化合物および方法
JP2020507761A (ja) 2017-01-31 2020-03-12 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 炎症系疾患の生化学的エンドタイプを定義するａｌｘ受容体リガンド
WO2020076578A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US309533A (en) * 1884-12-23 Saw-tooth-swaging device
US54761A (en) * 1866-05-15 Improved egg-beater
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
WO2000054767A1 (en) * 1999-03-18 2000-09-21 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response
AU780114B2 (en) * 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
ES2246230T3 (es) * 1999-03-18 2006-02-16 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina y su utilizacion.
WO2003039533A1 (en) 2001-11-06 2003-05-15 The Brigham And Women's Hospital, Inc. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases

Also Published As

Publication number Publication date
WO2000055109A1 (en) 2000-09-21
AU3743100A (en) 2000-10-04
DK1163204T3 (da) 2005-12-19
WO2000055109A9 (en) 2001-12-27
HK1043357A1 (en) 2002-09-13
JP2002539181A (ja) 2002-11-19
EP1163204A1 (en) 2001-12-19
HK1043357B (en) 2005-12-09
ATE303355T1 (de) 2005-09-15
US20080064747A1 (en) 2008-03-13
CA2365204A1 (en) 2000-09-21
US6659282B2 (en) 2003-12-09
CA2365204C (en) 2009-10-27
US20100048702A1 (en) 2010-02-25
US7227031B2 (en) 2007-06-05
AU2008207590A1 (en) 2008-09-25
ES2246230T3 (es) 2006-02-16
US8022105B2 (en) 2011-09-20
EP1163204B1 (en) 2005-08-31
AU776271B2 (en) 2004-09-02
US6720354B2 (en) 2004-04-13
US20070259958A1 (en) 2007-11-08
US6433202B1 (en) 2002-08-13
US20030191332A1 (en) 2003-10-09
AU2008207590B2 (en) 2010-12-16
US20030069435A1 (en) 2003-04-10
US7579494B2 (en) 2009-08-25
DE60022327D1 (de) 2005-10-06
US6960674B2 (en) 2005-11-01
US20050192350A1 (en) 2005-09-01
CA2675416A1 (en) 2000-09-21
US7615576B2 (en) 2009-11-10
PT1163204E (pt) 2005-11-30
US20030055275A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
DE60022327T2 (de) Lipoxinverbindungen und ihre anwendung
DE69711894T2 (de) Lipoxinverbindungen und deren verwendung zur behandlung der zellenwucherungsstörung
DE60124256T3 (de) Aspirin-ausgelöste lipidmediatoren
DE60024242T2 (de) Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion
DE69837295T2 (de) Bernsteinsäureester von Probucol zur Hemmung der Expression von VCAM-1
DE3884517T2 (de) Biologisch aktive Carbonsäureester.
DE69107153T2 (de) Isoprenoide Phospholipase A2 Inhibitoren und sie enthaltende Zusammensetzungen.
DE69528291T2 (de) Nicht-beta oxidierbare fettsäureanaloge,deren verwendung als therapeutisch wirksame medikamente sowie deren herstellung
DE69029654T2 (de) Verwendung von lipoxin a 4? und dessen derivaten als antagonisten für trägreagierende anaphylaxmittel
DE69210410T2 (de) Retinoid enthaltende dermatologische und/oder kosmetische zusammensetzungen
DE60224276T2 (de) Krebsmetastasen-hemmer mit carbacyclischen phosphatidinsäurederivaten
DE69706241T2 (de) Pharmazeutische Zusammensetzung zur Behandlung der Leukämie enthaltend 9-cis-Retinoinsäure-alpha-Tocopherolester
EP0477552A1 (de) Verwendung von 10-Ring-Lactonen als Lipidregulatoren
DE2244885A1 (de) Serumlipidkonzentration-erniedrigende verbindungen und verfahren zu deren herstellung
DE3933523A1 (de) Antimetastatisch wirkende mittel
EP1586550A1 (en) Lipoxin compounds and their use
EP1049707A1 (de) Ustilipide, verfahren zu deren herstellung sowie deren verwendung
US20120010286A1 (en) Prevention of neutrophil recruitment
HK1075246A (en) Lipoxin compounds and their use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition